What You Need to Know About Prostate Cancer
Prostate cancer is one of the most common cancers among men in the United States, second only to skin cancer. Many people have heard about prostate cancer, but not everyone fully understands it. The good news is that with early detection and advancements in treatment,...
Plant-Based Diets and Disease Progression in Men With Prostate Cancer _
Authors: Vivian N. Liu, MAS; Erin L. Van Blarigan, ScD; Li Zhang, PhD; Rebecca E. Graff, ScD; Stacy Loeb, MD; Crystal S. Langlais, PhD; Janet E. Cowan, MA; Peter R. Carroll, MD, MPH; June M. Chan, ScD; Stacey A. Kenfield, ScD This article examines whether...
Information About COVID-19 for Prostate Cancer Patients
COVID-19, short for coronavirus disease 2019, is an infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is a newly identified pathogen that has not previously been seen in humans and is highly contagious. Though it belongs to...
U.S. Congress Increases Funding for Prostate Cancer Research for FY 2020
To foster more research projects in prostate cancer, the U.S. Congress has increased funding for the Department of Defense’s Prostate Cancer Research Program (PCRP) by $10 million, to $110 million, for fiscal year 2020. To read the full article click here.
Celebs in Parody Video Urge Support for Movember to Raise Prostate Cancer Awareness
In a lighthearted twist on a serious goal of raising awareness and funds for prostate cancer, the Movember Foundation is again encouraging gents to join glitterati in celebrating the moustache. The annual event is called Movember, a blending of the Australian-English...
Brachytherapy Beneficial in Low Risk Prostate Cancer
Low-dose-rate (LDR) brachytherapy with or without androgen deprivation therapy may be the optimal treatment option for men with T1c to T3a prostate cancer (PCa), according to a new retrospective study published in Oncology Letters. For full article click HERE.
FDA Approves Erleada to Treat Metastatic Castration-Sensitive Prostate Cancer
The U.S. Food and Drug Administration (FDA) has approved Erleada (apalutamide) for the treatment of men with metastatic castration-sensitive prostate cancer (mCSPC), or those whose cancer still responds to androgen deprivation therapy (ADT). To read the full article...
Largest-ever African American Prostate Cancer Study Seeks Participants
African American men recently diagnosed with prostate cancer are being recruited across the U.S. for the largest-ever prostate cancer study in this ethnic group. The study is a joint effort by prostate cancer researchers and experts from around the country and will...
Prostate Cancer’s Risk and Mortality Dropping or Stabilizing
Prostate cancer’s incidence and deadliness has declined or stabilized in much of the world in recent years, with the greatest decrease in risk evident in the U.S., a study reports. Read full article here.
Patient Survey on Impact of Prostate Cancer
Men who are diagnosed with prostate cancer at later stages of the disease are more likely to say that their disease has affected several aspects of their life, including their self-esteem, how they share feelings with others, and how they feel about their sexual...
Bucking Landmark U.S. Recommendation, Oncologist Urges PSA Screening
Despite a United State Preventative Service Task Force 2012 conclusion that routine tests for prostate cancer are unnecessary, a prominent oncologist believes such screenings should be encouraged. Click HERE to read the full article.
Prostate Cancer Scoring Method May Not Accurately Predict Outcomes in Black Men
Black men diagnosed with prostate cancer are 2 times more likely to actually have a more aggressive, fatal form of the disease than those of other races, suggesting that the current prostate cancer score method may be underestimating the risk of death among black...
Top Ten Steps to Fight Prostate Cancer
If you have been diagnosed with prostate cancer, these steps will help you understand what to do next.
10-Year Survival of Young Low- and Intermediate-risk Prostate Cancer Patients Better with Radiation than Surgery
Radiation Therapy approaches — including brachytherapy and external beam radiation therapy (EBRT) — lead to better 10-year survival rates than prostate surgery in young patients with low- and intermediate-risk prostate cancer, a study shows. The research,...
Prostate Cancer Free Foundation Study Update
The Prostate Cancer Free Foundation has published an updated version of the comparative analysis study. The update represents the treatment outcomes of over 119,000 men. Click here for the update:
PSA TESTING CUTS DEATHS, Shows Value of Long Term Screening
The longest screening study on prostate cancer shows blood test measuring the levels of PSA, a well-known marker of prostate cancer, cuts deaths from the disease by nearly 30%. The study followed 20,000 men in Sweden for more than two decades and was featured...
Study Shows Radiation Treatments Delay Metastasis, Recurrence in Aggressive Prostate Cancers
A recent study shows that patients with aggressive forms of prostate cancer, who undergo radiation therapy- including external beam radiation therapy and brachytherapy- experience longer periods of time before metastasis or cancer...
Support the Foundation while you shop for the holidays
Black Friday and Cyber Monday are two of the busiest shopping days of the year. Support us when you shop on Amazon on Black Friday, Cyber Monday and the holiday season. Begin your Amazon shopping on this link: smile.amazon.com/ch/27-4434212 and Amazon donates to the...
75% of men with slow-growing prostate cancer fail to get appropriate follow-up
A recent study out of Australia found that nearly 3 out of 4 men with slow-growing prostate cancer, that chose to pursue active surveillance, are not receiving the appropriate follow-up to monitor the disease. These men are not getting the follow-up they need, and in...
3 in 4 Americans are Unaware Prostate Cancer Doesn’t Have Early Symptoms
When it comes to Prostate Cancer awareness, we have a ways to go here in the US. Recent study found that nearly 3 out of 4 Americans are unaware that early-stage prostate cancer has a lack of noticeable symptoms, and less than one-third know that men could receive...
Prostate Cancer Diagnosis – Do You Really Know “All” Your Treatment Options?
A Prostate Cancer diagnosis can be devastating and understanding the available treatment options can be overwhelming and is often more perplexing and confusing than the diagnosis itself. Leading to the confusion, there are many treatment options for prostate cancer,...
PCa Commentary
Expert Commentary On The Latest Prostate Cancer Topics
Written by Dr. Ed Weber
PCa Commentary is a well-researched, clearly presented commentary targeted to medical providers and others interested in current prostate cancer treatment. Each PCa Commentary edition offers an analysis of new developments in the field of prostate cancer with essays discussing and evaluating treatment management options for this disease.
PCa Commentary #215 – Low Testosterone After Successful Treatment – Is Replacement Testosterone Safe?
Any man who has undergone androgen deprivation therapy - ADT - to suppress his prostate cancer will have suffered some or all the associated adverse effects of diminished testosterone: fatigue, hot flushes, cognitive decline, bone density loss, erectile dysfunction,...
PCa Commentary #214 – Artera AI — “Prostate Test”: A Validated Tool to Assist in Treatment Decisions.
After a biopsy diagnosis of prostate cancer, supported by an MRI and Ga 68PET/CT, if the disease is localized to the prostate, the initial decision is whether to treat the cancer with surgery or radiation therapy or defer to active surveillance. Treatment is...
PCa Commentary #213 – METASTASIS DIRECTED THERAPY (MDT) — A Second Chance for Long-Term Disease Control With or Without Androgen Depression. And New Strategies for Avoiding ADT.
Following primary therapy with surgery or radiation in men with high-intermediate-risk and high-risk prostate cancer at diagnosis, the disease will recur in 20 - 30%. The recurrences may involve a small number of metastatic lesions, <5 sites or a few more. When...
PCa Commentary #212 – Mutations in DNA Damage Repair Genes – What Are They and Their Clinical Significance
Identifying mutations in the DNA Damage Repair (DDR) genes BRCA 1 & 2, ATM, PALB2 and CHEK2 carries clinical significance and opportunities. These genes (and several others) cooperate in repairing single-and double-strand DNA breaks, that if not corrected, impair...
PCa Commentary #211 – OSTEOPOROSIS: Androgen Suppression’s Unseen Liability
Androgen Deprivation Therapy, (ADT) for Treatment of Prostate Cancer can lead to an unseen liability, loss of bone density or osteoporosis. Prostate cancer suppression with Lupron and other testosterone lowering agents (ADT) has been long-recognized and widely...
PCa Commentary #210 – Metastases Directed Therapy (MDT) — An Update: Second Chance for Long-term Disease Control
A world-wide meta-analysis of the efficacy and safety of MDT in treatment of oligometastatic prostate cancer (omPC) was presented at the 2025 ASCO Genitourinary Cancers Symposium by Chad Tang comparing MDT+ ADT + Androgen Receptor Pathway Inhibitors (ARPI; i.e.,...
PCa Commentary #209 – Pluvicto (177 Lutetium PSMA) — Advanced To “Up Front” in Multiple Combinations.
The initial Vision Trial of Pluvicto enrolled men with advanced metastatic prostate cancer who had been heavily pretreated. About 50% of men benefited with a PSA reduction of >50%. Median overall survival for Pluvicto treated men was 15.3 months compared to 11.3...
PCa Commentary #208 – Adrogen Deprivation Therapy (ADT) – Cintinuous or Intermittent: That is the Question – or Possibly… no ADT Until Metastases.
Trials and reviews comparing intermittent androgen deprivation (IAD) to continuous androgen deprivation (CAD) have been ongoing for more than twenty years, with the near consensus that the survival outcome of both treatments are equivalent. Many studies have compared...
PCa Commentary #207 – The Emergence of Genomic Classifiers in Risk Stratification for Management of Prostate Cancer
Increasingly there have been advances in refining stratifications to better guide treatment decisions. Analysis of a cancer’s gene expression provides insight into a tumor’s behavior and aggressiveness, matching a therapy’s appropriateness, and allowing avoidance of...
PCa Commentary #206 – The BRCA Family of Mutated DNA Damage Repair Genes Influence Therapy
A rapid increase has occurred in discovery of biomarkers to guide therapeutic decisions. A mutated BRCA2 gene, for example, is a predictive biomarker that indicates greater cancer aggressiveness and a poor response to some therapies. But it also offers benefit when...
Remission versus Recurrence?
Relapse of prostate cancer is way more common than you might think. Many men treated for prostate cancer have their cancer return, which can lead to a lifetime of treatment. Prostate Cancer Free studies treatment outcomes documented in "The STUDY", recently updated for 2021. Take this Study to your doctor, and discuss your chance of cancer recurrence. The Study is available with the new, just released booklet, to help you learn about prostate cancer. Both the Prostate Cancer Free Study and the booklet, “What You Need to Know About Prostate Cancer” are available NOW for you to VIEW, PRINT or DOWNLOAD.
Help To Continue the Work!
The Prostate Cancer Free Foundation, reviews the results of hundreds of thousands of men treated for prostate cancer. Tracking them for years. This information is available to you, and others like you, to help find the best prostate cancer treatment. This work takes time, effort, resources all of it done by volunteers. Please help us continue. Please Donate!